Insider Selling: Vir Biotechnology, Inc. (NASDAQ:VIR) Director Sells 10,960 Shares of Stock

Vir Biotechnology, Inc. (NASDAQ:VIR) Director Vicki L. Sato sold 10,960 shares of the business’s stock in a transaction dated Wednesday, January 8th. The stock was sold at an average price of $12.52, for a total transaction of $137,219.20. Following the transaction, the director now owns 1,312,391 shares in the company, valued at $16,431,135.32. The trade was a 0.83 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Vir Biotechnology Trading Up 58.2 %

Vir Biotechnology stock traded up $4.59 during mid-day trading on Wednesday, hitting $12.48. The company’s stock had a trading volume of 39,456,292 shares, compared to its average volume of 8,750,732. The stock’s fifty day moving average is $8.08 and its two-hundred day moving average is $8.31. The firm has a market capitalization of $1.72 billion, a PE ratio of -3.18 and a beta of 0.51. Vir Biotechnology, Inc. has a 1 year low of $6.56 and a 1 year high of $14.45.

Vir Biotechnology (NASDAQ:VIR) last issued its quarterly earnings data on Thursday, October 31st. The company reported ($1.56) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.05) by ($0.51). Vir Biotechnology had a negative return on equity of 36.71% and a negative net margin of 678.40%. The business had revenue of $2.38 million for the quarter, compared to analyst estimates of $5.54 million. During the same period in the previous year, the business posted ($1.22) earnings per share. The firm’s revenue for the quarter was down 9.8% compared to the same quarter last year. On average, equities analysts expect that Vir Biotechnology, Inc. will post -3.36 EPS for the current fiscal year.

Institutional Trading of Vir Biotechnology

Institutional investors have recently added to or reduced their stakes in the stock. Barclays PLC lifted its position in shares of Vir Biotechnology by 1.3% during the third quarter. Barclays PLC now owns 550,186 shares of the company’s stock worth $4,121,000 after purchasing an additional 7,287 shares in the last quarter. State Street Corp lifted its holdings in Vir Biotechnology by 10.4% during the 3rd quarter. State Street Corp now owns 5,625,533 shares of the company’s stock worth $42,135,000 after buying an additional 530,645 shares in the last quarter. Quarry LP boosted its position in Vir Biotechnology by 901.8% in the 3rd quarter. Quarry LP now owns 17,000 shares of the company’s stock valued at $127,000 after buying an additional 15,303 shares during the period. Jacobs Levy Equity Management Inc. grew its stake in shares of Vir Biotechnology by 10.6% in the third quarter. Jacobs Levy Equity Management Inc. now owns 350,265 shares of the company’s stock worth $2,623,000 after acquiring an additional 33,473 shares in the last quarter. Finally, Erste Asset Management GmbH purchased a new stake in shares of Vir Biotechnology during the third quarter worth $217,000. Institutional investors and hedge funds own 65.32% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently commented on VIR. Needham & Company LLC reaffirmed a “buy” rating and issued a $19.00 price target on shares of Vir Biotechnology in a report on Wednesday, November 20th. HC Wainwright reaffirmed a “buy” rating and issued a $110.00 target price on shares of Vir Biotechnology in a research note on Wednesday, November 20th. Finally, Barclays lowered their price target on shares of Vir Biotechnology from $28.00 to $26.00 and set an “overweight” rating on the stock in a research report on Monday, November 4th. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat, Vir Biotechnology currently has an average rating of “Moderate Buy” and a consensus price target of $36.40.

About Vir Biotechnology

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).